anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Larimar Therapeutics · pitchdeck

Larimar Therapeutics | Investor Presentation Deck | 44 slides

44 pages · 4 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Larimar Therapeutics | Investor Presentation Deck | 44 slides

Larimar Therapeutics · 2023-11
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 44 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides Traction 41 slides 100% 41/41 slides 100% 41/41 slides · 196 hits
— 0/41 slides
26.8% 11/41 slides · 15 hits 14.6% 6/41 slides 100% 41/41 slides · 43 hits 19.5% 8/41 slides Executive Summary 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides · 2 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

44
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a list-based layout to present key company milestones and financial health.summarize
Open slide detailBeat · Executive Summary
04
The slide uses a two-column layout to contrast the current Phase 2 trial status with the upcoming OLE trial status.show_traction
Open slide detailBeat · Traction
05
The slide uses a timeline framework to demonstrate long-term IP protection.cite_precedent
Open slide detailBeat · Traction
06
The slide uses a medical context to establish the severity of the condition and the unmet medical need.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
The slide uses clinical data to establish the biological rationale for the therapeutic approach.establish_context
Open slide detailBeat · TractionLoop · Cost Of Inaction
08
The slide uses a visual comparison of protein structures to explain the mechanism of action.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
09
Details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose levels.analyze_data
Open slide detailBeat · TractionLoop · Golden Circle
10
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration changes from baseline.analyze_data
Open slide detailBeat · Traction
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.plan_implementation
Open slide detailBeat · Traction
12
Data represents median and 25th/75th percentiles. Baseline values provided in footnotes.show_traction
Open slide detailBeat · Traction
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.analyze_data
Open slide detailBeat · Traction
14
The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.analyze_data
Open slide detailBeat · Traction
15
FACOMS: Friedreich's Ataxia Clinical Outcome Measures Studyplan_implementation
Open slide detailBeat · TractionLoop · Quick Win Big Bet
16
The slide outlines a clinical development roadmap with specific trial types and status updates.plan_implementation
Open slide detailBeat · TractionLoop · Quick Win Big Bet
17
The slide highlights the unique 'Protein replacement' approach of Nomlabofusp compared to other modalities like Mitochondrial Oxidative Stress Modifiers, Gene Ecompare_peers
Open slide detailBeat · TractionLoop · Quick Win Big Bet
18
show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
19
The slide uses a list-based layout to present key company milestones and status.summarize
Open slide detailBeat · Traction
20
state_next_steps
Open slide detailBeat · Traction
21
appendix
Open slide detailBeat · Traction
22
other
Open slide detailBeat · Traction
23
The slide serves as a credibility-building asset by showcasing a partnership with a key non-profit organization in the rare disease space.establish_context
Open slide detailBeat · Traction
24
appendix
Open slide detailBeat · Traction
25
The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.analyze_data
Open slide detailBeat · Traction
26
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose cohorts (25mg, 50mg, 100mg).analyze_data
Open slide detailBeat · Traction
27
The charts display median values with 25th and 75th percentile error bars.show_traction
Open slide detailBeat · Traction
28
The table displays n (%) for categorical variables and descriptive statistics (mean, SD, median, range) for age.analyze_data
Open slide detailBeat · Traction
29
MAD likely stands for Multiple Ascending Dose.analyze_data
Open slide detailBeat · Traction
30
The slide highlights the safety profile of the drug candidate, specifically noting the absence of serious adverse events and the nature of injection site reactishow_traction
Open slide detailBeat · Traction
31
MAD = Multiple Ascending Dose. PK = Pharmacokinetics.analyze_data
Open slide detailBeat · Traction
32
transition
Open slide detailBeat · Traction
33
The slide outlines a 28-day treatment schedule with specific administration days highlighted in green.plan_implementation
Open slide detailBeat · Traction
34
The slide presents two visualizations: a dot plot with error bars for longitudinal data and a waterfall plot for individual subject response at Day 14.show_traction
Open slide detailBeat · Traction
35
The slide presents two distinct visualizations: a point-range plot for longitudinal data and a waterfall plot for individual subject response.analyze_data
Open slide detailBeat · Traction
36
The slide highlights that demographics are similar between Phase 1 and Phase 2 trials.analyze_data
Open slide detailBeat · Traction
37
Data presented as n, mean (SD), median, Q1/Q3, and min/max.analyze_data
Open slide detailBeat · Traction
38
analyze_data
Open slide detailBeat · Traction
39
transition
Open slide detailBeat · Traction
40
Kaplan-Meier survival curve showing efficacy of FXN replacement therapy.show_traction
Open slide detailBeat · Traction
41
The slide highlights key preclinical efficacy outcomes for the drug candidate CTI-1601.show_traction
Open slide detailBeat · Traction
42
Includes two charts: a bar chart for hFXN concentration and a dot plot with error bars for SDH activity.present_solution
Open slide detailBeat · Traction
43
Data shows significant differences (****) between vehicle and CTI-1601 treated KO mice.illustrate_case
Open slide detailBeat · Traction
44
The slide uses two line charts to demonstrate efficacy in two different cardiac metrics (Ejection Function and Fractional Shortening) over an 8-week period.show_traction
Open slide detailBeat · Traction